Colorectal Cancer | Specialty

The OncLive Colorectal Cancer condition center page is a comprehensive resource for clinical news and expert insights on colorectal cancer treatment and management, with a focus on novel therapeutic strategies including checkpoint inhibitors and TKIs across lines of therapy. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in colorectal cancer.

Road Map to Reducing Colorectal Cancer Deaths

August 20th 2020

Newer, cheaper and more personalized tests means more people tested and more lives saved.

Dr. Halfdanarson on Molecular Differences Between Left- Versus Right-Sided Tumors in CRC

August 12th 2020

Thorvardur (Thor) Halfdanarson, MD, discusses the molecular differences between left- versus right-sided tumors in colorectal cancer.

Blood-Based Assay Could Soon Surface in Colorectal Cancer

August 4th 2020

Shai Friedland, MD, discusses the novel multimodal FirstSight test, which showed promise in identifying colorectal cancer, as well as precancerous polyps and advanced adenomas.

KEYNOTE-177 Cements Pembrolizumab as New Standard of Care in MSI-H/dMMR mCRC

August 4th 2020

Thierry Andre, MD, discusses the results of the KEYNOTE-177 trial in metastatic colorectal cancer.

Adding Celecoxib to FOLFOX Does Not Demonstrate DFS Benefit in Colon Cancer

August 4th 2020

Jeffrey A. Meyerhardt, MD, MPH, FASCO, discusses the addition of celecoxib to standard chemotherapy, stating that it did not significantly improve disease-free survival or overall survival in patients with colon cancer.

Lenz Lends Insight on Therapeutic Approaches Shaking Up Third-Line CRC Treatment

August 3rd 2020

Heinz-Josef Lenz, MD, FACP, discusses third-line treatment approaches that are generating excitement in colorectal cancer.

Dr. Lenz on Later-Line Combo Approaches in CRC

July 28th 2020

Heinz-Josef Lenz, MD, FACP, discusses third-line treatment combination approaches in colorectal cancer.

Dr. Ahn on Limitations of Targeted Therapy in CRC

July 24th 2020

Daniel H. Ahn, DO, an oncologist, internist, and assistant professor of medicine at Mayo Clinic, discusses current limitations of targeted therapy in the colorectal cancer.

Dr. Lenz on Choosing Between Regorafenib and TAS-102 in CRC

July 23rd 2020

Heinz-Josef Lenz, MD, FACP, discusses factors to consider when choosing between regorafenib and trifluridine/tipiracil in the third-line treatment of patients with colorectal cancer.

Dr. Ahn on the KEYNOTE-177 Trial in Newly Diagnosed MSI-H/dMMR mCRC

July 23rd 2020

Daniel H. Ahn, DO, discusses updated findings from the phase 3 KEYNOTE-177 trial in patients with newly diagnosed microsatellite instability–high/mismatch repair deficient metastatic colorectal cancer.

Dr. Ahn on Advancing Actionable Alterations in CRC

July 17th 2020

Daniel H. Ahn, DO, discusses advancing actionable alterations in colorectal cancer.

Ahn Expands on Advances Made With Actionable Alterations in CRC

July 17th 2020

Daniel H. Ahn, DO, discusses the slew of actionable alterations that have emerged in colorectal cancer in recent years, including targeted therapies that are boosting survival outcomes.

Dr. Bach on Examining ctDNA in CRC

July 16th 2020

Sander Bach, MD, PhD, discusses research examining circulating tumor DNA in colorectal cancer.

Three Key ASCO Studies Showcase Targeted Advances

July 15th 2020

Molecularly targeted therapies showed practice-changing results for patients with biomarker-driven lung, colorectal, and ovarian cancers in phase 3 randomized clinical trial findings.

Dr. Bach Discusses Ongoing Research With ctDNA in CRC

July 15th 2020

Sander Bach, MD, PhD, discusses ongoing research with circulating tumor DNA in colorectal cancer.

Dr. Bach on the Results of a Systematic Review of ctDNA in CRC

July 14th 2020

Sander Bach, MD, PhD, discusses the results of a systematic review of circulating tumor DNA in colorectal cancer.

Dr. Ahn on Left- Versus Right-Sided Tumors in CRC

July 13th 2020

Daniel H. Ahn, DO, discusses left- versus right-sided tumors in colorectal cancer.

Dr. Kopetz on the Rationale for the BEACON CRC Study in BRAF V600E-Mutant mCRC

July 8th 2020

Scott Kopetz, MD, PhD, FACP, discusses the rationale for the phase 3 BEACON CRC trial in BRAF V600E-mutant metastatic colorectal cancer.

Dr. Siena on the Design of the DESTINY-CRC01 Trial in HER2+ Metastatic CRC

July 7th 2020

Salvatore Siena, MD, provides an overview of the DESTINY-CRC01 trial in DESTINY-CRC01 trial in HER2-positive metastatic colorectal cancer.

Dr. Bach on the Rationale to Conduct a Systematic Review of ctDNA in CRC

July 6th 2020

Sander Bach, MD, PhD, discusses the rationale to conduct a systematic review of circulating tumor DNA in colorectal cancer.